{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:54:39Z","timestamp":1761008079497,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jdiacomp.2022.108338","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:11:04Z","timestamp":1665403864000},"page":"108338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?"],"prefix":"10.1016","volume":"36","author":[{"given":"Djordje S.","family":"Popovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca Pantea","family":"Stoian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2022.108338_bb0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-022-01575-9","article-title":"Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes","volume":"21","author":"Davies","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108338_bb0010","doi-asserted-by":"crossref","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108338_bb0015","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00125-022-05659-9","article-title":"Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts","volume":"65","author":"Ruiz","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2022.108338_bb0020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/a-1392-0590","article-title":"Double diabetes: a growing problem requiring solutions","volume":"130","author":"Popovic","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.jdiacomp.2022.108338_bb0025","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/dom.14631","article-title":"Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: not any more?","volume":"24","author":"Czupryniak","year":"2022","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722002501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722002501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:17:26Z","timestamp":1761005846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872722002501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1056872722002501"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108338","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108338"}}